Gradalis, Inc.

One-third of all the regenerative medicine advanced therapy (RMAT) designations granted by the US Food and Drug Administration’s Center for Biologics Evaluation and Research were awarded in fiscal yea

PharmaMar SA suffered its second development setback in recent weeks, reporting Jan. 18 that Zepsyre (lurbinectedin) failed a Phase III clinical study in platinum-resistant ovarian cancer. The Spa

The ovarian cancer market will experience significant growth over the next five years as novel therapies complete pivotal trials and make their way through regulatory agencies; the value of the US mar

New At The Helm Company Changes ANDRE , Patrick, PhD To: Pliant Therapeutics Inc. , VP, Biology (April) From: Merck Sharp & Dohme Corp., Principal Scientist Phone: 650-481-6708 BRENNEMAN , Rya